EDCTP at ASTMH 2024

Symposium

The safety, efficacy and transmission blocking effect of artemether-lumefantrine +atovaquone-proguanil for uncomplicated malaria
14 November 2024 | 08:00-09:45 (CDT)

EDCTP project highlighted:

• ASAAP (EDCTP2 and Global Health EDCTP3)

Neglected Tropical Diseases: Getting the Dose Right
14 November 2024 | 10:15-12:00 (CTD)

EDCTP project highlight:

• VirTUAL (EDCTP2)

Ganaplacide® (KAF156) A Next-Generation, Non-Artemisinin, for the Treatment of P falciparum Malaria
15 November 2024 | 13:45-15:30 (CDT)

EDCTP project highlighted:

• WANECAM-2 (EDCTP2)

Advancing research to improve treatment of neglected tropical diseases in children
15 November 2024 | 13:45-15:30 (CDT)

EDCTP project highlighted:

• ACOZI-KIDS (EDCTP2)
  More information about this session »

Capacity building for genomics and Data Sharing in Africa (The MalariaGEN vision)
15 November 2024 | 18:00-20:00 (CDT)

EDCTP project highlighted:

• EGSAT (EDCTP2)

Innovative tools for the control of NTDs. How to achieve impact through access beyond drug donations
16 November 2024 | 08:00-09:45 (CDT)

EDCTP projects highlighted:

• STOP2030 (Global Health EDCTP3)
• STOP1 and STOP2 (EDCTP2)
• MoxiMultiDose Mode (EDCTP2)
• PZQ4PSAC (EDCTP2)

Improving the Diagnosis and Management of Severe Malaria
16 November 2024 | 08:00-09:45 (CDT)

EDCTP projects highlighted:

• PDMC Saves Lives (Global Health EDCTP3)
• PDMC-II (EDCTP2)

Implementing Perennial Malaria Chemoprevention across Africa: Converging to Consensus?
16 November 2024 | 08:00-09:45 (CDT)

EDCTP project highlighted:

• MULTIPLY (EDCTP2)

Reaching for elimination: Critical challenges in targeting transmission in malaria-endemic settings
16 November 2024 | 12:45-14:30

EDCTP project highlighted:

• PfTBV (EDCTP2)

Will HAT be the next NTD to achieve global elimination?
17 November 2024 | 11:30-13:15

EDCTP projects highlighted:

• FEX-g-HAT (EDCTP2)
• HAT-r-ACC (EDCTP2)
• ACOZI-KIDS (EDCTP2)
  More information about this session »

Genomic surveillance and evolution of ART-R in West Africa
16 November 2024 | 17:15-19:00

EDCTP project highlighted:

• EGSAT (EDCTP2)

Scientific sessions

Partial clearance of pre-established Plasmodium falciparum infection in mosquitoes by mimicking a bloodmeal on treated patients with Artemether+Lumefantrine + Atovaquone-Proguanil
Priscilla Adjei-Kusi | EDCTP2 project: ASAAP
14 November 2024 | 08:00-09:45

New insights on selection of malaria parasites revealed by genomes of oldest archived Plasmodium falciparum population samples
Alfred Ngwa | EDCTP2 project: EGSAT
14 November 2024 | 15:00-16:45

Improving Antimalarial Drug Efficacy assessment: Comparative Analysis of Length Polymorphic Markers and Classification Algorithms in two Phase II Clinical Trial
Daniela Montero Salas | EDCTP2 project: PAMAfrica
14 November 2024 | 17:15-19:00

RH5.1/Matrix-M™: Efficacy of a standalone blood-stage vaccine against clinical P. falciparum malaria in 5-17 month old children: a Phase 2b randomized trial in Burkina Faso
Hamtandi Natama | EDCTP2 project: MMVC
15 November 2024 | 16:00-15:45

Poster sessions

Possible effect of neutropenia on the efficacy of artemisinin-based combination therapy in pregnant women in Mali
Moussa Djimdé | EDCTP2 project: PYRAPREG

Community-based strategies to increase uptake of Intermittent Preventive Treatment in Pregnancy with Sulfadoxine-Pyrimethamine in sub-Saharan Africa: A systematic review, meta-analysis, meta-ethnography, and economic assessment
Kadiatou Koita | EDCTP2 project: INTEGRATION

Effectiveness of ANC delivery of IPTp-SP in the context of a trial of integrated ANC and community delivery of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in Mali and Burkina Faso
Kadiatou Koita | EDCTP2 project: INTEGRATION

Characterization of the immune responses induced by the Plasmodium falciparum Blood-Stage Vaccine Candidate, RH5.1/Matrix M™, in a Phase IIb trial in Burkinabe 5-17month olds
Sarah Silk | EDCTP2 project: MMVC

Caregiver perception and acceptability of the malaria vaccine RTS,S prior to introduction in the Far North region of Cameroon
Innocent Mbulli Ali | EDCTP2 project: VIBRANT

An update of the epidemiological parameters of malaria in school age children in Kolle, a rural setting, Mal
Sidibe Bouran | EDCTP2 project: WANECAM-2

Evaluation of the efficacy of artemisinin-based combination therapies on Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale infections in Mali
Kone Souleymane B | EDCTP2 project: WANECAM-2

Comparative Evaluation of Antimalarial Drug Efficacy in Three Study Sites in Mali
Fatoumata Ousmane Maiga | EDCTP2 project: WANECAM-2

KALUMI – An adaptive run-in cohort of a Phase II trial to evaluate food-effects of ganaplacide/ lumefantrine in adolescent patients
lssaka Sagara | EDCTP2 project: WANECAM-2

KALUMI – A Phase II trial to evaluate the efficacy, safety and tolerability of the novel anti-malarial drug ganaplacide/lumefantrine in pediatric patients
lssaka Sagara | EDCTP2 project: WANECAM-2

Pharmacokinetics, Safety, and Efficacy of a New Formulation of Artemether-Lumefantrine in the Treatment of Acute Uncomplicated Plasmodium falciparum Malaria in Neonates/Infants <5 kg Body Weight: Primary Results From Phase 2/3 CALINA Trial
Gildas Wounounou | EDCTP2 project: PAMAfrica

Symptom Profile of Infants and Neonates <5 kg Body Weight Diagnosed With Plasmodium falciparum Malaria and Enrolled in the Phase 2/3 CALINA Study
Preetam Gandhi | EDCTP2 project: PAMAfrica

Application of the rapid diagnostic test based on loop-mediated isothermal amplification (RLDT) for Shigella and enterotoxigenic Escherichia coli (ETEC) detection in childhood diarrhea in Burkina Faso
Alimatou Héma | EDCTP2 project: ShigaPlexIM

Fexinidazole in patients with human African trypanosomiasis due to Trypanosoma brucei rhodesiense, towards an arsenic-free, first-line therapy
Olaf Valverde Mordt | EDCTP2 project: HAT-r-ACC

Impact of natural exposure to P. falciparum on IgG responses against a panel of malaria vaccine candidate antigens in children with uncomplicated malaria episodes in the Banfora health district, Burkina Faso
Sem Ezinmegnon | EDCTP2 project: MIMVaC-Afrique

Prevalence of haplotypes associated with resistance of Plasmodium falciparum to Dihydroartemisinin-Piperaquine, Sulfadoxine-pyrimethamine and Amodiaquine during seasonal malaria chemo-prevention campaigns among children aged 6-15 years in Mali
Karim Traore | EDCTP2 project: RCB-DHAPQ-SMC

Beyond Ebola virus and Lassa virus in Guinea: mNGS reveals broad viral diversity in epidemic hemorrhagic fever cases through surveillance activities
Karifa Kourouma | EDCTP2 project: ALEERT

Spatial hospital based seroprevalence and risk of infection from Plasmodium vivax and other Plasmodium species using multiplex quantitative suspension array assay in Cameroon
Innocent Mbulli Ali | EDCTP2 project: VIBRANT

Ex vivo drug response of Plasmodium falciparum to Artemisinin-based Combination Therapy Partner drugs in Ghana
Samirah Saiid | EDCTP2 project: EGSAT

Assessing drug resistance profile and associated markers in Gambian P. falciparum isolates
Ndey Fatou | EDCTP2 project: EGSAT

Other

Consortium annual meeting
International PfSPZ Consortium Meeting (i-PfSPZ-C)
Issaka Sagara | EDCTP2 project: PfTBV
12 November 2024

Young Investigator Award
Alimatou Héma | EDCTP2 project: ShigaPlexIM
13 November 2024 | 09:00-14:00